BeOne Medicines said on Wednesday that the U.S. Food and Drug Administration has approved its drug for a type of blood cancer.
U.S.-listed shares of the company were up more than 1% in afternoon trade.
The drug, branded as Beqalzi, was greenlit to treat relapsed or refractory mantle cell lymphoma, an aggressive cancer of the lymphatic system, which contains disease-fighting white blood cells, that relapses after initial treatment or fails to respond to it.
The regulator’s accelerated approval was based on a early-to-mid stage study in which the drug showed a complete response, or disappearance of all detectable signs of cancer, in 16% of the patients on the drug.
Leave a Reply